Profuse oral secretions after propafenone administration in neonates

Area of Science:

• Neonatal pharmacology
• Pediatric cardiology
• Adverse drug reactions

Background:

• Propafenone is an antiarrhythmic medication commonly used for supraventricular tachycardias.
• Known adverse effects include proarrhythmic and systemic complications.
• The safety profile in neonates requires further investigation.

Observation:

• Three newborns experienced significant adverse events after receiving oral propafenone.
• The neonates presented with profuse oral secretions.
• Respiratory distress was observed, requiring medical intervention.

Findings:

• A novel adverse effect of oral propafenone in neonates is reported.
• The adverse events included excessive salivation and breathing difficulties.
• These reactions were severe enough to warrant stopping propafenone treatment.

Implications:

• This highlights a previously unrecognized risk associated with oral propafenone in the neonatal population.
• Clinicians should be vigilant for these specific adverse effects in infants treated with propafenone.
• Further research into neonatal propafenone dosing and adverse event profiles is warranted.